The SELECT trial, published in 2023, enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes
El Beshlawy, A., Abd, El Raouf, Mostafa, F., Talaat, M., Isma'eel, H., Aoun, E., Hoffbrand, A
Las opciones hoy en da son numerosas y cada una de ellas podrn adaptarse mejor a su necesidad dependiendo de la dificultad o tipo de construccin que necesite llevar a cabo en su vivienda o espacio de trabajo
For example, they'll cover Ozempic for type 2 diabetes more readily than for weight loss (which is an "off-label" use)
Orforglipron, a once-daily oral GLP-1 pill, led to an average weight loss of 11.2% over 72 weeks, along with improvements in blood pressure, triglycerides, and cholesterol